Seborrheic Keratoses

FDA Approves ESKATA Topical SK Treatment

New treatment for raised seborrheic keratoses

The U.S. Food and Drug Administration (FDA) has approved Aclaris Therapeutics’ ESKATA (hydrogen peroxide) topical solution, 40% for the treatment of raised seborrheic keratoses (SKs). The proprietary, high-concentration hydrogen peroxide-based topical solution is applied directly to the raised SKs by a healthcare provider using a pen-like applicator. The approval was based on two pivotal Phase 3 trials that demonstrated the safety and efficacy of ESKATA for the treatment of raised SKs.